PMN
ProMIS Neurosciences Inc.Key Statistics
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is an innovative biotechnology company focused on developing transformative therapeutic solutions for neurodegenerative diseases, particularly Alzheimer's and amyotrophic lateral sclerosis (ALS). Leveraging its proprietary protein engineering platform, the firm identifies and targets misfolded proteins linked to these debilitating conditions, delivering the potential for groundbreaking treatments with enhanced safety profiles. With a diverse pipeline of drug candidates progressing through various stages of development, ProMIS stands at the forefront of neurotherapeutic advancements, poised to address significant unmet medical needs and exert a meaningful impact within the biopharmaceutical landscape.
Fundamentals
| Revenue (TTM) | 7,560 |
| Gross Profit (TTM) | $-33.38M |
| EBITDA | $-13.31M |
| Operating Margin | 0.00% |
| Return on Equity | -522.00% |
| Return on Assets | -176.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.58 |
| Price-to-Book | 17.28 |
| Price-to-Sales (TTM) | 4016.22 |
| EV/Revenue | 4004.98 |
| EV/EBITDA | -1.74 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $8.97M |
| Float | $4.60M |
| % Insiders | 20.43% |
| % Institutions | 32.77% |
Historical Volatility
Volatility is currently expanding